Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia

A novel PCM1-FGFR1 gene rearrangement was identified in a patient with a myeloid neoplasm with eosinophilia. Futibatinib, an oral selective small molecule inhibitor of FGFR1-4, resulted in a durable complete hematologic and cytogenetic remission.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Kasbekar, Monica, Nardi, Valentina, Dal Cin, Paola, Brunner, Andrew M., Burke, Meghan, Chen, Yi-Bin, Connolly, Christine, Fathi, Amir T., Foster, Julia, Macrae, Molly, McAfee, Steven L., McGregor, Kristin, Narayan, Rupa, Ramos, Aura Y., Som, Tina T., Vartanian, Meghan, Friedman, Robb S., Benhadji, Karim A., Hobbs, Gabriela S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Exceptional Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362377/
https://ncbi.nlm.nih.gov/pubmed/32649766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002308
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados